8. Huntington disease
[
110 clinical trials,
125 drugs（DrugBank:
50 drugs),
87 target genes / 146 target pathways ]
Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04102579 | November 2019 | 11 November 2019 | Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington's Disease | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington's Disease | Chorea, Huntington | Drug: Valbenazine;Drug: Placebo | Neurocrine Biosciences | Huntington Study Group | Recruiting | 18 Years | 75 Years | All | 120 | Phase 3 | United States |
| 2 | NCT04071639 | October 20, 2019 | 30 September 2019 | Symptomatic Therapy for Patients With Huntington's Disease | Randomized Clinical Trial to Evaluate the Efficacy and Safety of Symptomatic Drug Therapy for Mild to Moderate Huntington's Disease Patients | Huntington Disease | Drug: Haloperidol;Drug: Risperidone;Drug: Zoloft;Drug: Coenzyme Q10 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | N/A | N/A | All | 100 | Phase 1 | China | |
| 3 | NCT04000594 | September 2, 2019 | 22 October 2019 | A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease | An Open-Label, Adaptive Multiple-Dose Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease | Huntingtons Disease | Drug: RO7234292 (RG6042) | Hoffmann-La Roche | Recruiting | 25 Years | 65 Years | All | 20 | Phase 1 | United Kingdom | |
| 4 | NCT03980938 | July 8, 2019 | 29 July 2019 | Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease | A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD) | Huntington Disease | Drug: neflamapimod;Other: Placebo | EIP Pharma Inc | Voisin Consulting, Inc. | Recruiting | 30 Years | 70 Years | All | 16 | Phase 2 | United Kingdom |
| 5 | NCT03842969 | April 23, 2019 | 11 November 2019 | An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Patients Who Participated in Prior Roche and Genentech Sponsored Studies | An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intrathecally Administered RO7234292 (RG6042) in Patients With Huntington's Disease | Huntington Disease | Drug: RO7234292 (RG6042) | Hoffmann-La Roche | Recruiting | 25 Years | N/A | All | 950 | Phase 3 | United States;Canada;Germany;Spain;United Kingdom | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT03854019 | April 1, 2019 | 29 April 2019 | Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease | Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease | Huntington Disease;Irritability | Drug: Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg);Drug: Placebo | The University of Texas Health Science Center, Houston | Cures Within Reach | Recruiting | 18 Years | 75 Years | All | 22 | Phase 3 | United States |
| 7 | NCT03787758 | February 28, 2019 | 22 October 2019 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B | A Phase 1, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Healthy Adults With an Open-label Cohort of Patients With Huntington's Disease | Huntington Disease | Drug: SAGE-718 | Sage Therapeutics | Recruiting | 18 Years | 70 Years | All | 10 | Phase 1 | United States | |
| 8 | EUCTR2016-005095-10-DK | 26/02/2019 | 30 April 2019 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease | Huntington's Disease MedDRA version: 20.0 Level: PT Classification code 10070668 Term: Huntington's disease System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-120101 Product Code: WVE-120101 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: WVE-120101 Current Sponsor code: WVE-120101 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 8- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intrathecal use | Wave Life Sciences Ltd. | Authorised | Female: yes Male: yes | 48 | Phase 1;Phase 2 | France;Canada;Poland;Australia;Denmark;Germany;United Kingdom | |||
| 9 | NCT03761849 | January 23, 2019 | 4 November 2019 | A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease | A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease | Huntingtons Disease | Drug: RO7234292;Drug: Placebo | Hoffmann-La Roche | Recruiting | 25 Years | 65 Years | All | 660 | Phase 3 | United States;Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;China | |
| 10 | NCT03764215 | November 15, 2018 | 18 December 2018 | Nilotinib in Huntington's Disease | An Open Label, Phase Ib Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability and Biomarkers in Huntington's Disease | Huntington Disease | Drug: Nilotinib 150 MG | Georgetown University | Recruiting | 25 Years | 90 Years | All | 10 | Phase 1 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | EUCTR2017-002471-25-GB | 18/10/2018 | 28 February 2019 | An extension study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the study drug, RO7234292 (ISIS 443139), in patients who participated in prior investigational studies of RO7234292 | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7234292 (ISIS 443139) IN HUNTINGTON'S DISEASE PATIENTS WHO PARTICIPATED IN PRIOR INVESTIGATIONAL STUDIES OF RO7234292 (ISIS 443139) | Early Manifest Huntington's Disease MedDRA version: 20.0 Level: PT Classification code 10070668 Term: Huntington's disease System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Code: Ro 723-4292/F02 Pharmaceutical Form: Solution for injection INN or Proposed INN: n.a. CAS Number: 1709886-74-7 Current Sponsor code: RO7234292 Other descriptive name: RG6042, formerly ISIS 443139, IONIS-HTTRx Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6- | F.Hoffmann La-Roche Ltd | Not Recruiting | Female: yes Male: yes | 46 | Phase 1;Phase 2 | Canada;Germany;United Kingdom | |||
| 12 | NCT03575676 | August 8, 2018 | 30 September 2019 | Efficacy and Safety of SOM3355 in Huntington's Disease Chorea | Phase IIa, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of SOM3355 in Huntington's Disease (HD) Patients With Chorea Movements. | Huntington's Chorea | Drug: SOM3355 100mg BID;Drug: SOM3355 200mg BID;Drug: Placebo BID | SOM Biotech SL | Not recruiting | 18 Years | N/A | All | 32 | Phase 2 | Spain | |
| 13 | NCT02509793 | August 1, 2018 | 30 September 2019 | A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine) | A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine) | Huntington's Disease | Drug: Tetrabenazine | William Ondo, MD | H. Lundbeck A/S | Recruiting | 18 Years | 80 Years | All | 20 | Phase 4 | United States |
| 14 | EUCTR2018-000203-16-ES | 18/06/2018 | 20 August 2018 | Phase IIa, double-blind, randomized, placebo-controlled study of the efficacy and safety of SOM3335 in Huntington`s disease (HD) patients with chorea movements. | Phase IIa, double-blind, randomized, placebo-controlled study of the efficacy and safety of SOM3335 in Huntington`s disease (HD) patients with chorea movements. | Chorea movements associated with Huntington's Disease MedDRA version: 20.0 Level: LLT Classification code 10020469 Term: Huntington's chorea System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Calvan® 100 mg Pharmaceutical Form: Tablet INN or Proposed INN: BEVANTOLOL HYDROCHLORIDE CAS Number: 42864-78-8 Current Sponsor code: SOM3355 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | SOM Biotech | Authorised | Female: yes Male: yes | 30 | Phase 2 | Spain | |||
| 15 | NCT03252535 | January 15, 2018 | 23 April 2019 | Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease | Dose-Response Evaluation of the Investigational Product Cellavita HD After Intravenous Administration in Patients With Huntington's Disease | Huntington Disease | Biological: Cellavita HD lower dose;Biological: Cellavita HD higher dose;Other: Placebo | Azidus Brasil | Cellavita Pesquisa Científica Ltda | Recruiting | 21 Years | 65 Years | All | 35 | Phase 2 | Brazil |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | EUCTR2017-002471-25-DE | 10/01/2018 | 4 December 2018 | An extension study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the study drug, RO7234292 (ISIS 443139), in patients who participated in prior investigational studies of RO7234292 | An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington’s Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139) | Early Manifest Huntington's Disease MedDRA version: 20.0 Level: PT Classification code 10070668 Term: Huntington's disease System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Code: Ro 723-4292/F02 Pharmaceutical Form: Solution for injection INN or Proposed INN: n.a. CAS Number: 1709886-74-7 Current Sponsor code: RO7234292 Other descriptive name: RG6042, formerly ISIS 443139, IONIS-HTTRx Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6- | F.Hoffmann La-Roche Ltd | Authorised | Female: yes Male: yes | 46 | Phase 2 | Canada;Germany | |||
| 17 | NCT03342053 | November 27, 2017 | 4 November 2019 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139) | An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139) | Huntington's Disease | Drug: RO7234292 (RG6042) | Hoffmann-La Roche | Not recruiting | 25 Years | N/A | All | 46 | Phase 2 | Canada;Germany;United Kingdom | |
| 18 | NCT02728115 | October 16, 2017 | 23 April 2019 | Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease | First in Human Study to Evaluate Safety of Cellavita HD Investigational Product After Intravenous Application in Participants With Huntington's Disease | Huntington Disease | Biological: Cellavita HD Lower Dose;Biological: Cellavita HD Higher dose | Azidus Brasil | Cellavita Pesquisa Científica Ltda;Azidus Brasil Scientific Research and Development Ltda | Not recruiting | 21 Years | 65 Years | Male | 6 | Phase 1 | Brazil |
| 19 | NCT03296176 | October 9, 2017 | 16 December 2017 | Metabolomic Study in Huntington's Disease (METABO-HD) | Metabolomic Study in Huntington's Disease | Huntington Disease | Biological: blood sample | University Hospital, Angers | Recruiting | 20 Years | 70 Years | All | 150 | N/A | France | |
| 20 | NCT03225833 | July 17, 2017 | 22 July 2019 | Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients With Huntington's Disease | Huntington's Disease | Drug: WVE-120101;Drug: Placebo | Wave Life Sciences Ltd. | Recruiting | 25 Years | 65 Years | All | 48 | Phase 1/Phase 2 | Australia;Canada;Denmark;Poland;United Kingdom | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT03225846 | July 17, 2017 | 22 July 2019 | Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients With Huntington's Disease | Huntington's Disease | Drug: WVE-120102;Drug: Placebo | Wave Life Sciences Ltd. | Recruiting | 25 Years | 65 Years | All | 48 | Phase 1/Phase 2 | Australia;Canada;Denmark;Poland;United Kingdom | |
| 22 | NCT03515213 | April 27, 2017 | 18 March 2019 | Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease | A Phase IIa, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease | Huntington Disease | Drug: Fenofibrate;Drug: Placebo | University of California, Irvine | Not recruiting | 18 Years | N/A | All | 20 | Phase 2 | United States | |
| 23 | NCT03019289 | April 19, 2017 | 18 March 2019 | A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease | A Phase I, Open-Label, Single-Dose, Adaptive (S)-(-)-[18F]Fluspidine and [18F]Fallypride Positron Emission Tomography Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease | Health Volunteers, Huntington Disease | Drug: pridopidine (90 mg) | Prilenia Therapeutics Development Ltd. | Not recruiting | 25 Years | N/A | Male | 23 | Phase 1 | Germany | |
| 24 | EUCTR2016-003730-25-NL | 14/02/2017 | 12 February 2018 | A study to assess the safety and efficacy of a new medicine SBT-020 in patients with Early Stage Huntington’s Disease. | A Two Part Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SBT-020 in Patients with Early Stage Huntington’s Disease. - SBT-020 in HD | Huntington's Disease MedDRA version: 20.0 Level: PT Classification code 10070668 Term: Huntington's disease System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: SBT-020 Product Code: SBT-020 Pharmaceutical Form: Lyophilisate for solution for injection INN or Proposed INN: SBT-020 CAS Number: 1795737-00-6 Current Sponsor code: SBT-020-01 Other descriptive name: SS-20 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 5-25 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Stealth Bio Therapeutics Inc | Not Recruiting | Female: yes Male: yes | 24 | Phase 2 | Netherlands | |||
| 25 | NCT02507284 | May 10, 2016 | 4 November 2019 | Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease | An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD) | Irritable Mood;Huntington's Disease | Drug: SRX246;Drug: Placebo | Azevan Pharmaceuticals | National Institute of Neurological Disorders and Stroke (NINDS);NeuroNEXT Network | Not recruiting | 18 Years | N/A | All | 106 | Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT02907294 | March 2016 | 26 September 2016 | Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 After Multiple Oral Doses in Healthy Volunteers | Randomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 (160 mg and 320 mg) After Multiple Oral Doses in Healthy Volunteers | Huntington Disease | Drug: PBF-999 / 160 mg;Drug: PBF-999 / 320 mg;Drug: Placebo | Palobiofarma SL | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Not recruiting | 18 Years | 45 Years | Both | 8 | Phase 1 | Spain |
| 27 | EUCTR2014-005112-42-NL | 11/12/2015 | 29 January 2018 | A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3) | A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3) | Huntington's disease MedDRA version: 20.0 Level: PT Classification code 10070668 Term: Huntington's disease System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | Product Name: Triheptanoin Product Code: UX007 Pharmaceutical Form: Oral solution Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use | INSERM | Authorised | Female: yes Male: yes | 100 | Phase 2 | Netherlands | |||
| 28 | NCT02494778 | September 24, 2015 | 18 March 2019 | A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients With Huntington's Disease (Open PRIDE-HD) | Huntington's Disease | Drug: Pridopidine | Prilenia Therapeutics Development Ltd. | Not recruiting | 21 Years | N/A | All | 248 | Phase 2 | United States;Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;Denmark | |
| 29 | NCT02519036 | August 6, 2015 | 11 June 2019 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 443139 in Patients With Early Manifest Huntington's Disease | Huntington's Disease | Drug: ISIS 443139 10 mg;Drug: ISIS 443139 30 mg;Drug: ISIS 443139 60 mg;Drug: ISIS 443139 90 mg;Drug: ISIS 443139 120 mg;Other: Placebo | Ionis Pharmaceuticals, Inc. | Not recruiting | 25 Years | 65 Years | All | 46 | Phase 1/Phase 2 | Canada;Germany;United Kingdom | |
| 30 | NCT02336633 | July 2015 | 2 September 2019 | Resveratrol and Huntington Disease | Metabolic Intervention Using Resveratrol in Patients With Huntington Disease | Huntington Disease | Dietary Supplement: Resveratrol;Other: Placebo | Assistance Publique - Hôpitaux de Paris | Not recruiting | 18 Years | N/A | All | 102 | N/A | France | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | NCT02481674 | July 2015 | 6 May 2019 | A Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Pepinemab (VX15/2503) | A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503 | Huntington's Disease | Drug: VX15/2503;Drug: Placebo | Vaccinex Inc. | Huntington Study Group | Not recruiting | 21 Years | N/A | All | 301 | Phase 2 | United States;Canada |
| 32 | NCT02453061 | June 29, 2015 | 29 July 2019 | A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease | A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease | Huntington Disease | Drug: Triheptanoin oil;Drug: Placebo | Institut National de la Santé Et de la Recherche Médicale, France | Ultragenyx Pharmaceutical Inc | Not recruiting | 18 Years | N/A | All | 100 | Phase 2 | France;Netherlands |
| 33 | NCT02342548 | February 25, 2015 | 11 June 2018 | Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021 | An Open Label Extension Study To Investigate The Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Previously Completed Study A8241021 | Huntington's Disease | Drug: 20 mg BID of PF-02545920 | Pfizer | Not recruiting | 30 Years | 66 Years | All | 188 | Phase 2 | United States;Canada;Germany;Poland;United Kingdom | |
| 34 | NCT02215616 | November 24, 2014 | 15 October 2018 | A Clinical Study in Subjects With Huntington's Disease to Assess Efficacy and Safety of Three Oral Doses of Laquinimod | A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as Treatment in Patients With Huntington's Disease | Huntington's Disease | Drug: Laquinimod;Drug: Placebo | Teva Branded Pharmaceutical Products, R&D Inc. | Not recruiting | 21 Years | 55 Years | All | 352 | Phase 2 | United States;Canada;Czechia;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;Czech Republic;France;India;Israel | |
| 35 | NCT02231580 | September 1, 2014 | 28 January 2019 | Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients | A Dose Escalation, Proof of Concept, Phase IIa Study to Investigate the Safety and Tolerability, the Pharmacokinetic and the Pharmacodynamic of BN82451B, Administered Twice Daily Over 4 Weeks, in Male Patients With Huntington's Disease | Huntington's Disease | Drug: Placebo;Drug: BN82451B | Ipsen | Not recruiting | 20 Years | 70 Years | Male | 17 | Phase 2 | Germany | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | NCT01834053 | September 2014 | 19 February 2015 | Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea. | Safety and Efficacy of Bone Marrow Derived MNCs for the Treatment of Huntingtons Chorea. It is Self Funded (Patients' Own Funding) Clinical Trial | Huntington Disease | Biological: autologous Stem Cell | Chaitanya Hospital, Pune | Recruiting | 35 Years | 44 Years | Both | 50 | Phase 1/Phase 2 | India | |
| 37 | NCT02197130 | September 2014 | 16 December 2017 | Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease | A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease | Huntington's Disease | Drug: PF-02545920;Other: Placebo | Pfizer | Not recruiting | 30 Years | 65 Years | All | 272 | Phase 2 | United States;Canada;Germany;Poland;United Kingdom | |
| 38 | NCT02208934 | September 2014 | 11 April 2016 | Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers | Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 ( 5 mg, 10 mg, 20 mg and 40 mg ) in Healthy Young Male Volunteers | Huntington's Disease | Drug: PBF-999;Drug: Placebo | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Palo Biofarma, S.L | Not recruiting | 18 Years | 45 Years | Male | 32 | Phase 1 | Spain |
| 39 | EUCTR2013-002899-41-DE | 28/04/2014 | 22 May 2017 | Study to assess the effects of BN82451B and how it is absorbed, distributed and eliminated in the body, when it is given for 4 weeks to men suffering from Hungtington's disease | A dose escalation, proof of concept, phase IIa study to investigate the safety and tolerability, the pharmacokinetic and the pharmacodynamic of BN82451B, administered twice daily over 4 weeks, in male patients with Huntington’s disease | Huntington's disease MedDRA version: 18.1 Level: PT Classification code 10070668 Term: Huntington's disease System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BN8251B Pharmaceutical Form: Capsule INN or Proposed INN: N/A CAS Number: 918656-59-4 Current Sponsor code: BN82451B Other descriptive name: BN82451B Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: BN8251B Pharmaceutical Form: Capsule INN or Proposed INN: N/A CAS Number: 918656-59-4 Current Sponsor code: BN82451B Other descriptive name: BN82451B Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Ipsen Pharma | Not Recruiting | Female: no Male: yes | Phase 2 | Germany | ||||
| 40 | NCT02006472 | February 28, 2014 | 18 March 2019 | A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease | Huntington's Disease | Drug: Pridopidine;Other: Placebo | Prilenia Therapeutics Development Ltd. | European Huntington's Disease Network;Huntington Study Group | Not recruiting | 21 Years | N/A | All | 408 | Phase 2 | United States;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | EUCTR2013-001888-23-GB | 22/01/2014 | 1 December 2014 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 17.1 Level: PT Classification code 10070668 Term: Huntington's disease System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 Pharmaceutical Form: Capsule INN or Proposed INN: pridopidine CAS Number: 882737-42-0 Current Sponsor code: TV-7820 Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 22.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Pridopidine Product Code: TV-7820 Pharmaceutical Form: Capsule INN or Proposed INN: pridopidine CAS Number: 882737-42-0 Current Sponsor code: TV-7820 Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 45- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Teva Branded Pharmaceutical Products R&D, Inc | Authorised | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands | |||
| 42 | EUCTR2013-002545-10-SE | 08/01/2014 | 27 June 2016 | An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g Parkinson’s disease, Huntington’s disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy. | An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g Parkinson’s disease, Huntington’s disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy. - OSU6162Open1309 | Parkinsons disease Huntingtons disease Multiple scleros Brain trauma Stroke Myalgic encephalomyelitis Narcolepsy;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: OSU6162 similar to (-)-OSU 6162 Pharmaceutical Form: Coated tablet | A. Carlsson Research AB | Authorised | Female: yes Male: yes | 240 | Phase 2 | Sweden | |||
| 43 | NCT01897896 | November 12, 2013 | 16 December 2017 | Alternatives for Reducing Chorea in HD | An Open-Label, Long Term Safety Study of SD-809 ER in Subjects With Chorea Associated With Huntington Disease | Chorea Associated With Huntington Disease | Drug: SD-809 | Auspex Pharmaceuticals, Inc. | Not recruiting | 18 Years | N/A | All | 119 | Phase 3 | United States;Canada;Australia | |
| 44 | NCT01806896 | September 2013 | 16 December 2017 | Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease | A Phase 2, Double-blind Randomized, Sequential Treatment Group, Placebo-controlled Study To Evaluate The Safety, Tolerability And Brain Cortico-striatal Function Of 2 Doses Of Pf-02545920 In Subjects With Early Huntington's Disease | Huntington's Disease | Drug: PF-02545920;Drug: Placebo | Pfizer | Not recruiting | 18 Years | 70 Years | All | 37 | Phase 2 | France | |
| 45 | NCT01795859 | August 5, 2013 | 16 December 2017 | First Time Use of SD-809 in Huntington Disease | A Randomized Double-Blind, Placebo-Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease | Chorea | Drug: SD-809;Drug: Placebo | Teva Pharmaceutical Industries | Not recruiting | 18 Years | N/A | All | 90 | Phase 3 | United States;Australia;Canada | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | NCT01882062 | May 2013 | 19 October 2017 | Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease | Huntington Disease | Drug: Triheptanoin 1g/kg/day | Institut National de la Santé Et de la Recherche Médicale, France | Not recruiting | 18 Years | N/A | All | 10 | Phase 2 | France | ||
| 47 | NCT01834911 | March 2013 | 11 June 2018 | Effect of Tetrabenazine on Stroop Interference in HD | Effect of Tetrabenazine on Stroop Interference in Huntington Disease | Huntington Disease | Drug: Tetrabenazine withdrawal | New York Medical College | Not recruiting | 18 Years | N/A | All | 2 | Phase 4 | United States | |
| 48 | NCT01696708 | December 6, 2012 | 16 December 2017 | Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease | Study of the Brain Energy Profile Evolution, Using 31Phosphorus-Nuclear Magnetic Resonance Spectroscopy, at Different Stages of Huntington Disease | Huntington Disease | Other: 31-Phosphorus RMN Spectroscopy | Institut National de la Santé Et de la Recherche Médicale, France | Not recruiting | 18 Years | N/A | All | 50 | N/A | France | |
| 49 | NCT01914965 | June 2012 | 19 February 2015 | Apathy Cure Through Bupropion in Huntington's Disease | A Randomized, Double-blind, Placebo-controlled Prospective Crossover Trial Investigating the Efficacy and Safety of the Treatment With Bupropion in Patients With Apathy in Huntington's Disease | Apathy;Huntington's Disease | Drug: Bupropion;Drug: Placebo | Charite University, Berlin, Germany | University of Ulm;Ruhr University of Bochum;University Hospital Muenster | Not recruiting | 25 Years | 75 Years | Both | 40 | Phase 2 | Germany |
| 50 | NCT01590888 | April 2012 | 19 October 2017 | Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease | A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease | Huntington Disease | Drug: PBT2;Drug: Placebo | Prana Biotechnology Limited | Not recruiting | 25 Years | N/A | All | 109 | Phase 2 | United States;Australia | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | NCT01573819 | November 24, 2011 | 16 December 2017 | A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278 | A Randomised, Placebo Controlled, Ascending, Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278 | Huntington Disease | Drug: GSK356278;Drug: Placebo | GlaxoSmithKline | Not recruiting | 18 Years | 65 Years | All | 36 | Phase 1 | Netherlands | |
| 52 | NCT01602900 | November 22, 2011 | 16 December 2017 | Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease | An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain PDE4 Engagement, Pharmacokinetics and Safety of Single Oral Doses of GSK356278, Using 11C-(R)-Rolipram as a PET Ligand(s) | Huntington Disease | Drug: GSK356278;Drug: Rolipram | GlaxoSmithKline | Not recruiting | 22 Years | 55 Years | Male | 8 | Phase 1 | United Kingdom | |
| 53 | NCT01485965 | November 2011 | 19 February 2015 | A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease | A Phase 1b, Open-label, Parallel-group Study in Subjects With Huntington Disease to Assess the Safety, Tolerability, and Fed/Fasted Pharmacokinetics of Repeated Oral Doses of SEN0014196 | Huntington's Disease | Drug: SEN0014196 | Siena Biotech S.p.A. | Not recruiting | 25 Years | 65 Years | Both | 26 | Phase 1 | United States | |
| 54 | NCT01521585 | November 2011 | 7 December 2015 | A Phase II Safety and Tolerability Study With SEN0014196 | A Double-blind, Placebo-controlled Study in Huntington's Disease Patients to Determine the Safety and Tolerability of SEN0014196 | Huntington's Disease | Drug: SEN0014196;Drug: Placebo | Siena Biotech S.p.A. | Not recruiting | 30 Years | 70 Years | Both | 144 | Phase 2 | Germany | |
| 55 | EUCTR2011-001131-23-DE | 21/09/2011 | 2 December 2013 | A study to determine how safe and tolerable the study drug is, when given to patients with Huntingtons Disease. | A double-blind, placebo-controlled study in Huntington’s Disease patients to determine the safety and tolerability of SEN0014196 - N/A | Huntington's disease MedDRA version: 14.1 Level: PT Classification code 10070668 Term: Huntington's disease System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: SEN0014196 Product Code: SEN0014196 Pharmaceutical Form: Tablet INN or Proposed INN: selisistat CAS Number: 49843-98-3 Current Sponsor code: SEN0014196 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: SEN0014196 Product Code: SEN0014196 Pharmaceutical Form: Tablet INN or Proposed INN: selisistat CAS Number: 49843-98-3 Current Sponsor code: SEN0014196 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Siena Biotech SpA | Not Recruiting | Female: yes Male: yes | 144 | Germany;Italy;United Kingdom | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 56 | NCT01458470 | September 2011 | 19 February 2015 | A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease | A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease; a Phase IIb Study | Huntington Disease | Drug: Memantine;Other: Placebo | University of British Columbia | Huntington Society of Canada;Huntington Study Group | Not recruiting | 18 Years | 75 Years | Both | 19 | Phase 2 | Canada |
| 57 | NCT01306929 | March 1, 2011 | 18 March 2019 | Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease | A Multi-Center, North American, Open-Label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington's Disease (Open-HART). | Huntington Disease | Drug: pridopidine | Prilenia Therapeutics Development Ltd. | Not recruiting | N/A | N/A | All | 235 | Phase 2 | United States;Canada | |
| 58 | NCT02101957 | October 2010 | 19 February 2015 | Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103) | Huntington's Disease | Drug: RP103;Drug: Placebo | University Hospital, Angers | Not recruiting | 18 Years | 65 Years | Both | 96 | Phase 2/Phase 3 | France | ||
| 59 | EUCTR2009-018119-14-GB | 23/07/2010 | 7 January 2013 | Huntington's Disease Rilmenidine Safety Trial - Huntington's Disease Rilmenidine study | Huntington's Disease Rilmenidine Safety Trial - Huntington's Disease Rilmenidine study | Huntington's Disease MedDRA version: 14.1 Level: PT Classification code 10070668 Term: Huntington's disease System Organ Class: 10010331 - Congenital, familial and genetic disorders | Trade Name: Hyperium Product Name: Rilmenidine Pharmaceutical Form: Tablet INN or Proposed INN: Rilmenidine CAS Number: 54187-04-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1mg- | Cambridge University Hospitals NHS Foundation Trust and University of Cambridge | Authorised | Female: yes Male: yes | 16 | United Kingdom | ||||
| 60 | EUCTR2010-019444-39-FR | 18/06/2010 | 19 March 2012 | Essai multicentrique de traitement de la maladie de Huntington par la cystéamine - CYST-HD | Essai multicentrique de traitement de la maladie de Huntington par la cystéamine - CYST-HD | Maladie de Huntington. MedDRA version: 12.1 Level: LLT Classification code 10020469 Term: Huntington's chorea | Product Name: Cysteamine Bitartrate Product Code: RP 103 Pharmaceutical Form: Capsule, hard CAS Number: 27761-19-9 Concentration unit: Other Concentration type: equal Concentration number: 221mg/capsule- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Centre Hospitalier Universitaire d'Angers | Authorised | Female: yes Male: yes | France | |||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 61 | EUCTR2009-018123-32-DE | 07/06/2010 | 4 March 2013 | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus | Huntington disease MedDRA version: 12.1 Level: LLT Classification code 10020469 Term: Huntington's chorea | Product Name: Dimebon Product Code: Dimebon Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Dimebon dihydrochloride CAS Number: 97657-92-6 Current Sponsor code: Dimebon Other descriptive name: Dimebon dihydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Product Name: Dimebon Product Code: Dimebon Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Dimebon dihydrochloride CAS Number: 97657-92-6 Current Sponsor code: Dimebon Other descriptive name: Dimebon dihydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- | Medivation, Inc | Not Recruiting | Female: yes Male: yes | 350 | Denmark;Netherlands;Germany;Italy;United Kingdom;Sweden | ||||
| 62 | NCT01411163 | April 2010 | 19 February 2015 | Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability | Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability | Huntington's Disease | Drug: Creatine monohydrate | Massachusetts General Hospital | National Institutes of Health (NIH) | Not recruiting | 26 Years | N/A | Both | 24 | Phase 2 | United States |
| 63 | NCT00920699 | February 2010 | 16 December 2017 | Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL) | A Multi-Center, Double-Blind, Randomized, Parallel Group Tolerability Study of Coenzyme Q10 (UbiquinonE)in PRE-manifest Huntington's Disease | Huntington's Disease | Drug: CoQ10 | Johns Hopkins University | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 18 Years | N/A | All | 90 | Phase 2 | United States |
| 64 | NCT01085266 | February 2010 | 24 October 2016 | An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease | Huntington Disease | Drug: Dimebon (latrepirdine) | Medivation, Inc. | Pfizer;Pfizer | Not recruiting | 30 Years | N/A | Both | 362 | Phase 3 | |
| 65 | EUCTR2009-011800-44-GB | 07/10/2009 | 14 August 2012 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZON | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZON | Huntington disease MedDRA version: 9.1 Level: LLT Classification code 10020469 Term: Huntington's chorea | Product Name: Dimebon Product Code: Dimebon Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Dimebon dihydrochloride CAS Number: 97657-92-6 Current Sponsor code: Dimebon Other descriptive name: Dimebon dihydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Dimebon Product Code: Dimebon Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Dimebon dihydrochloride CAS Number: 97657-92-6 Current Sponsor code: Dimebon Other descriptive name: Dimebon dihydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Medivation, Inc | Not Recruiting | Female: yes Male: yes | 350 | Phase 3 | Germany;United Kingdom;Netherlands;Denmark;Italy;Sweden | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 66 | NCT00975481 | October 2009 | 19 October 2017 | A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users | A Randomized, Double-Blind, Placebo- And Active-Controlled Single-Dose, Crossover Study To Evaluate The Abuse Potential Of Single Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users | Alzheimer's Disease;Huntington's Disease | Drug: dimebon;Drug: placebo;Drug: alprazolam | Pfizer | Medivation, Inc. | Not recruiting | 18 Years | 55 Years | All | 36 | Phase 1 | Canada |
| 67 | NCT00988624 | October 2009 | 19 February 2015 | A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine) | A Phase 1, Randomized, Open-Label, Single Dose Cross-Over Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine) | Alzheimer's Disease;Huntington Disease | Drug: Dimebon IR Tablet;Drug: Dimebon MR1;Drug: Dimebon MR2;Drug: Dimebon MR3;Drug: Dimebon MR4 | Pfizer | Medivation, Inc. | Not recruiting | 18 Years | 55 Years | Both | 20 | Phase 1 | United States |
| 68 | NCT00990613 | October 2009 | 19 February 2015 | A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin | A Phase 1, Fixed Sequence, Cross-Over Study To Investigate The Single Dose Pharmacokinetics Of A Dimebon (Latrepirdine) Transdermal Solution Relative To The Immediate Release Formulation In Older Adults | Alzheimer's Disease;Huntington's Disease | Drug: Dimebon IR;Drug: Dimebon Transdermal | Pfizer | Medivation, Inc. | Not recruiting | 50 Years | 85 Years | Both | 19 | Phase 1 | United States |
| 69 | NCT01521832 | October 2009 | 19 February 2015 | Escalating Dose Study in Healthy Volunteers With SEN0014196 | A Phase I, Randomised, Double-Blind, Placebo-Controlled, Two-Part Study Consisting of Single and Multiple Oral Dose Escalation to Determine, Safety, Tolerability and Pharmacokinetics of SEN0014196 | Huntington's Disease | Drug: SEN0014196 | Siena Biotech S.p.A. | Not recruiting | 18 Years | 65 Years | Both | 88 | Phase 1 | United Kingdom | |
| 70 | EUCTR2009-011743-39-DE | 18/09/2009 | 12 November 2012 | Efficacy, Safety and Tolerability of AFQ056 in Patients with Huntington's Disease in Reducing Chorea | A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration Proof of Concept study in patients with Huntington's disease to assess the efficacy, safety and tolerability of AFQ056 in reducing chorea | Huntington's disease MedDRA version: 13.1 Level: LLT Classification code 10020469 Term: Huntington's chorea System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AFQ056 Product Code: AFQ056 Pharmaceutical Form: Capsule, hard CAS Number: 543906-09-8 Current Sponsor code: AFQ056 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: AFQ056 Product Code: AFQ056 Pharmaceutical Form: Capsule, hard CAS Number: 543906-09-8 Current Sponsor code: AFQ056 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 60 | United States;Germany;United Kingdom | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 71 | NCT00712426 | September 2009 | 30 March 2015 | Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) | Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) | Huntington's Disease | Drug: Creatine Monohydrate;Drug: Placebo | Massachusetts General Hospital | University of Rochester;National Center for Complementary and Integrative Health (NCCIH) | Not recruiting | 18 Years | N/A | Both | 553 | Phase 3 | United States;Australia;Canada;New Zealand |
| 72 | NCT00980694 | September 2009 | 13 June 2016 | Bioavailability of Ubiquinol in Huntington Disease | Bioavailability of Ubiquinol in Huntington Disease | Huntington Disease | Dietary Supplement: ubiquinol | University of Rochester | Kaneka Corporation | Not recruiting | 18 Years | N/A | Both | 6 | Phase 1 | United States |
| 73 | NCT00920946 | July 2009 | 24 October 2016 | A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients With Mile-to-Moderate Huntington Disease | Huntington Disease | Drug: Dimebon;Other: Placebo | Medivation, Inc. | Pfizer;Pfizer | Not recruiting | 30 Years | N/A | Both | 403 | Phase 3 | United States;Australia;Canada;Denmark;Germany;Sweden;United Kingdom |
| 74 | NCT00931073 | July 2009 | 19 February 2015 | A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers | A Phase I, Open-Label, Three-Period, Fixed-Sequence Study To Estimate The Steady-State Effect Of Ketoconazole And Omeprazole On The Single-Dose Pharmacokinetics Of Dimebon [PF-01913539] In Healthy CYP2D6 EM And PM Subjects | Alzheimer's Disease;Huntington's Disease | Drug: Dimebon alone;Drug: Dimebon + Ketoconazole;Drug: Dimebon + Omeprazole | Pfizer | Medivation, Inc. | Not recruiting | 18 Years | 55 Years | Both | 24 | Phase 1 | United States |
| 75 | NCT00970229 | July 2009 | 16 December 2017 | Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects. | Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in Subjects With Parkinson Disease, Huntington Disease, and Healthy Controls | Parkinson Disease;Huntington Disease | Drug: [123I]MNI-420 | Institute for Neurodegenerative Disorders | Not recruiting | 18 Years | N/A | All | 19 | Phase 1 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 76 | NCT00907595 | May 2009 | 19 February 2015 | Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon | Treating Sleep Wake Cycle Disturbances in Basal Ganglia Neurodegenerative Disorder Subjects With Ramelteon- A Double Blind, Placebo Controlled Trial | Huntington's Disease;Parkinson's Disease;Dementia With Lewy Bodies;Sleep Disorders;Circadian Dysregulation | Drug: Ramelteon;Drug: Placebo | Massachusetts General Hospital | Not recruiting | 20 Years | 90 Years | Both | 0 | N/A | United States | |
| 77 | NCT01411150 | May 2009 | 19 February 2015 | Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study | Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study | Huntington's Disease | Drug: Creatine Monohydrate | Massachusetts General Hospital | National Institutes of Health (NIH) | Not recruiting | 26 Years | N/A | Both | 38 | Phase 2 | United States |
| 78 | NCT00632645 | April 2009 | 29 January 2018 | Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride | Neuroleptic and Huntington Disease. Comparison of : Olanzapine, la Tetrabenazine and Tiapride. A Multicentric, Randomised, Controlled Study. | Huntington Disease | Drug: Olanzapine;Drug: Xenazine;Drug: Tiapridal | Assistance Publique - Hôpitaux de Paris | Not recruiting | 18 Years | N/A | All | 180 | Phase 3 | France | |
| 79 | NCT00870974 | March 2009 | 16 December 2017 | A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions | Evaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric Conditions | Parkinson Disease;Huntington Disease;Autistic Spectrum Disorders;Fragile X Syndrome;Alzheimer Disease;Mild Cognitive Impairment | Drug: [18F]FPEB | Institute for Neurodegenerative Disorders | Not recruiting | 18 Years | 85 Years | All | 48 | Phase 1 | United States | |
| 80 | NCT00824590 | February 2009 | 19 February 2015 | A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function | A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function | Alzheimer's Disease;Huntington's Disease | Drug: Dimebon | Pfizer | Medivation, Inc. | Not recruiting | 18 Years | 75 Years | Both | 20 | Phase 1 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 81 | NCT00825084 | February 2009 | 19 February 2015 | A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects | A Phase 1, Randomized, Subject- And Investigator-Blind, Sponsor-Open, Placebo-Controlled, Parallel-Cohort, Single-Dose Escalation, And Multiple-Dose Titration Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects | Alzheimer's Disease;Huntington's Disease | Drug: Dimebon | Pfizer | Medivation, Inc. | Not recruiting | 18 Years | 55 Years | Both | 45 | Phase 1 | United States |
| 82 | NCT00827034 | February 2009 | 22 October 2018 | A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects | A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects | Alzheimer's Disease;Huntington's Disease | Drug: Warfarin;Drug: Dimebon | Pfizer | Medivation, Inc. | Not recruiting | 18 Years | 55 Years | All | 14 | Phase 1 | United States |
| 83 | NCT00831506 | February 2009 | 19 February 2015 | Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF-01913539) On The Safety, Tolerability, And Steady-State Pharmacokinetics Of Digoxin In Healthy Subjects | Alzheimer Disease;Huntington Disease | Drug: digoxin;Drug: dimebon | Pfizer | Medivation, Inc. | Not recruiting | 18 Years | 55 Years | Both | 12 | Phase 1 | United States |
| 84 | NCT00788047 | November 2008 | 19 February 2015 | A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan | A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon [PF-01913539] On The Single-Dose Pharmacokinetics Of The CYP2D6 Substrate Dextromethorphan In Healthy Subjects | Huntington Disease;Alzheimer Disease | Drug: Dextromethorphan;Drug: Dimebon + Dextromethorphan | Pfizer | Medivation, Inc. | Not recruiting | 18 Years | 55 Years | Both | 14 | Phase 1 | United States |
| 85 | NCT00724048 | October 2008 | 8 August 2016 | A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease | A Multi-center, North American, Randomized, Double-blind, Parallel Group Study Comparing Three Doses of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease (HART) | Huntington Disease | Drug: ACR16 10 mg;Drug: ACR16 22.5 mg;Drug: ACR16 45 mg;Other: Placebo | Teva Pharmaceutical Industries | Not recruiting | 30 Years | N/A | Both | 227 | Phase 2/Phase 3 | United States;Canada | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 86 | EUCTR2007-002977-30-FR | 02/09/2008 | 19 March 2012 | Essai multicentrique évaluant l'effet de la cystéamine sur le BDNF sérique dans la maladie de Huntington. - BDNF-HD | Essai multicentrique évaluant l'effet de la cystéamine sur le BDNF sérique dans la maladie de Huntington. - BDNF-HD | Maladie de Huntigton (MH): maladie neurodégénérative d’origine génétique. Elle associe des troubles moteurs, psychiatriques et cognitifs (dégénérescence neuronale dans le striatum). Aucun traitement validé n’existe à ce jour. MedDRA version: 9.1 Level: LLT Classification code 10020469 Term: Huntington's chorea | Trade Name: CYSTAGON Product Name: CYSTAGON Pharmaceutical Form: Capsule, hard | Centre Hospitalier Universitaire d'Angers | Authorised | Female: yes Male: yes | France | |||||
| 87 | NCT00665223 | April 2008 | 8 August 2016 | A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's Disease | A Multicentre, Multinational, Randomized, Double-blind, Parallel-group Study Comparing ACR16 Versus Placebo for the Symptomatic Treatment of Huntington's Disease | Huntington's Disease | Drug: ACR16;Drug: Placebo | Teva Pharmaceutical Industries | Not recruiting | 30 Years | N/A | Both | 437 | Phase 3 | Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom | |
| 88 | NCT00608881 | March 2008 | 19 October 2017 | Coenzyme Q10 in Huntington's Disease (HD) | Coenzyme Q10 in Huntington's Disease (HD) | Huntington's Disease | Drug: coenzyme Q10;Other: placebo | Massachusetts General Hospital | National Institute of Neurological Disorders and Stroke (NINDS);University of Rochester | Not recruiting | 16 Years | N/A | All | 609 | Phase 3 | United States;Australia;Canada |
| 89 | EUCTR2007-004988-22-GB | 11/01/2008 | 18 September 2012 | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | Huntington's Disease MedDRA version: 9.1 Level: LLT Classification code 10020469 Term: Huntington's chorea | Product Name: ACR16 Product Code: ACR16 Pharmaceutical Form: Capsule, hard Current Sponsor code: ACR16 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 45- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | NeuroSearch Sweden AB | Not Recruiting | Female: yes Male: yes | 420 | Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria | ||||
| 90 | NCT00592995 | December 2007 | 19 February 2015 | Creatine Safety and Tolerability in Premanifest HD: PRECREST | Creatine Safety and Tolerability in Premanifest HD: PRECREST | Huntington Disease | Drug: Creatine monohydrate;Drug: Placebo | Massachusetts General Hospital | Not recruiting | 26 Years | N/A | Both | 64 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 91 | EUCTR2007-003293-25-GB | 20/11/2007 | 19 March 2012 | A MULTI-CENTER, PHASE 2 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF DIMEBON IN SUBJECTS WITH HUNTINGTON’S DISEASE - DIMOND | A MULTI-CENTER, PHASE 2 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF DIMEBON IN SUBJECTS WITH HUNTINGTON’S DISEASE - DIMOND | Huntington's disease MedDRA version: 9.1 Level: LLT Classification code 10020469 Term: Huntington's chorea | Product Name: Dimebon Product Code: Dimebon Pharmaceutical Form: Tablet CAS Number: 3613-73-8 Current Sponsor code: Dimebon Other descriptive name: Dimebon Dihydrochloride Concentration unit: % (W/W) percent weight/weight Concentration type: equal Concentration number: 18%-22% Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Medivation, Inc. | Authorised | Female: yes Male: yes | 90 | Phase 2 | United Kingdom | |||
| 92 | NCT00514774 | August 2007 | 19 February 2015 | Ursodiol in Huntington's Disease | Ursodiol in Huntington's Disease | Huntington Disease | Drug: ursodiol;Drug: placebo | Oregon Health and Science University | Huntington Study Group;Huntington Society of Canada | Not recruiting | 18 Years | N/A | Both | 21 | Phase 1 | United States |
| 93 | NCT00497159 | July 2007 | 19 February 2015 | A Study of the Novel Drug Dimebon in Patients With Huntington's Disease | A Multi-Center, Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's Disease | Huntington's Disease | Other: Placebo;Drug: Dimebon | Medivation, Inc. | Huntington Study Group | Not recruiting | 29 Years | N/A | Both | 90 | Phase 2 | United States |
| 94 | NCT00387270 | October 2006 | 19 February 2015 | Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease | A Multicenter, Phase 1-2A, Open-Label, Dosage-Escalation and Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's Disease | Huntington's Disease | Drug: Dimebon | Medivation, Inc. | Huntington Study Group | Not recruiting | 18 Years | N/A | Both | 9 | Phase 1/Phase 2 | United States |
| 95 | NCT00277355 | April 2006 | 19 October 2017 | Pilot Study of Minocycline in Huntington's Disease | A Multi-Center, Double-Blind, Pilot Study of Minocycline in Huntington's Disease | Huntington Disease | Drug: minocycline;Drug: Matching placebo | Merit Cudkowicz | FDA Office of Orphan Products Development | Not recruiting | 18 Years | N/A | All | 114 | Phase 2/Phase 3 | United States;Canada |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 96 | EUCTR2005-002088-98-GB | 07/11/2005 | 1 May 2012 | Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease | Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease | HUNTINGTON’S DISEASE MedDRA version: 8.0 Level: LLT Classification code 10010331 | Product Name: Ethyl-EPA Product Code: LAX-101 Pharmaceutical Form: Capsule, soft Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use | Amarin Neuroscience Ltd | Not Recruiting | Female: yes Male: yes | Portugal;Germany;United Kingdom;Spain;Italy | |||||
| 97 | NCT00271596 | November 2005 | 19 October 2017 | Citalopram to Enhance Cognition in HD | A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD) | Huntington Disease;Chorea;Executive Dysfunction | Drug: 20mg daily citalopram;Drug: Placebo | University of Iowa | National Institute of Neurological Disorders and Stroke (NINDS);Cure Huntington's Disease Initiative (CHDI);University of Rochester;Mayo Clinic | Not recruiting | 18 Years | 75 Years | All | 33 | Phase 2 | United States |
| 98 | NCT00368849 | November 2005 | 19 October 2017 | Atomoxetine and Huntington's Disease | Atomoxetine for Attention Deficits in Adults With Mild HD: A Randomized, Placebo-Controlled Crossover Study | Huntington Disease;Chorea | Drug: atomoxetine;Drug: Matching Placebo | University of Iowa | Eli Lilly and Company | Not recruiting | 18 Years | 65 Years | All | 20 | Phase 2 | United States |
| 99 | NCT00146211 | September 2005 | 19 February 2015 | TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease | A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-Controlled Trial of Ethyl-EPA (Miraxion™) in Subjects With Mild to Moderate Huntington's Disease | Huntington Disease | Drug: Ethyl-EPA (Miraxion™) | Amarin Neuroscience Ltd | Huntington Study Group | Not recruiting | 35 Years | N/A | Both | 300 | Phase 3 | United States;Canada |
| 100 | NCT00212316 | August 2005 | 19 February 2015 | Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD) | Phenylbutyrate Development for Huntington's Disease (PHEND-HD): A Multi-Center, Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up to Determine the Safety and Tolerability of Phenylbutyrate in Subjects With Huntington's Disease | Huntington's Disease | Drug: sodium phenylbutyrate | University of Rochester | HP Therapeutics Foundation;Massachusetts General Hospital;Columbia University;University of Iowa;University of California, San Diego;University of Kansas;University of Alabama at Birmingham;Johns Hopkins University | Not recruiting | 18 Years | N/A | Both | 60 | Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 101 | NCT01412151 | April 2005 | 19 October 2017 | Creatine Safety & Tolerability in Huntington's Disease | Creatine Safety & Tolerability in Huntington's Disease (CREST-X): A Single-Center, Open-Label, Long-Term Safety & Tolerability Extension Study of Creatine in Subjects With HD | Huntington's Disease (HD) | Drug: Creatine monohydrate | Massachusetts General Hospital | Not recruiting | 18 Years | N/A | All | 10 | Phase 2 | United States | |
| 102 | NCT00095355 | October 2004 | 19 February 2015 | Effects of Lithium and Divalproex`on Brain-Derived Neurotrophic Factor in Huntington's Disease | Stimulation of Tyrosine Kinase and ERK Signaling Pathways in Huntington's Disease | Huntington's Disease | Drug: Lithium;Drug: Divalproex | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 35 | Phase 2 | United States | |
| 103 | EUCTR2004-000394-60-SE | 30/06/2004 | 19 March 2012 | A randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington disease | A randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington disease | ACR16 belongs to a new class of CNS active agents called dopaminergic stabilizers. Dopaminergic stabilizers are compounds that can both enhance and counteract dopamine dependent functions in the CNS, depending on the initial level of dopaminergic activity. The stabilizing feature of such compounds is illustrated by their interaction with dopaminergic agonists. | Product Name: ACR16 Product Code: ACR16 Pharmaceutical Form: Capsule* CAS Number: 346688-38-8 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | A. Carlsson Research AB | Not Recruiting | Female: yes Male: yes | 60 | Phase 2 | Denmark;Sweden | |||
| 104 | NCT00652457 | September 2003 | 19 February 2015 | Study of Memantine to Treat Huntington's Disease | A Pilot Study of Memantine for Cognitive and Behavioral Dysfunction in Huntington's Disease | Huntington's Disease | Drug: Memantine | University of California, San Diego | Forest Laboratories | Recruiting | 18 Years | N/A | Both | 60 | Phase 4 | United States |
| 105 | NCT00190450 | January 2002 | 16 December 2017 | MIG-HD: Multicentric Intracerebral Grafting in Huntington's Disease | Multicentric Intracerebral Grafting in Huntington's Disease | Huntington Disease | Biological: graft intracerebral of foetal neurons | Assistance Publique - Hôpitaux de Paris | Not recruiting | 18 Years | 65 Years | All | 54 | Phase 2 | France | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 106 | NCT00026988 | October 2001 | 19 February 2015 | Creatine Therapy for Huntington's Disease | Creatine Therapy for Huntington's Disease | Huntington's Disease | Drug: Creatine | National Center for Complementary and Integrative Health (NCCIH) | Not recruiting | 18 Years | N/A | Both | 64 | Phase 1/Phase 2 | United States | |
| 107 | NCT00029874 | September 2001 | 7 April 2015 | Minocycline in Patients With Huntington's Disease | Minocycline Dosing and Safety in Huntington's Disease | Huntington's Disease | Drug: Minocycline | FDA Office of Orphan Products Development | Not recruiting | 18 Years | N/A | Both | 63 | Phase 1/Phase 2 | United States | |
| 108 | NCT00219804 | January 2000 | 19 February 2015 | Efficacy and Safety of Tetrabenazine in Chorea | A Randomized, Double-Blind, Placebo-Controlled Study of Tetrabenazine for the Treatment of Huntington's Chorea | Huntington's Disease | Drug: tetrabenazine or placebo | Prestwick Pharmaceuticals | Not recruiting | 18 Years | N/A | Both | Phase 3 | |||
| 109 | NCT00277602 | November 1999 | 19 February 2015 | Riluzole in Huntington's Disease | A Phase III Multicenter, Double-Blind, Parallel-Group, Placebo Controlled Study to Measure the Effect of Riluzole 50 mg b.i.d. Over a Period of Three Years on the Progression of Huntington's Disease | Huntington Disease | Drug: Riluzole | Sanofi | Not recruiting | 25 Years | 65 Years | Both | 537 | Phase 3 | ||
| 110 | NCT00001930 | April 1999 | 19 February 2015 | Treatment of Huntington's Chorea With Amantadine | NMDA-Receptor Blockade in Huntington's Chorea | Chorea;Huntington's Disease | Drug: Amantadine | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 25 | Phase 2 | United States |